Clinical Trial Update: A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating gemcitabine, capecitabine, and bevacizumab in metastatic renal cell carcinoma was terminated; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University of Chicago | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: TERMINATED | Results posted: 2011-12-22